VIDEO REPORT: Aytu BioScience (NASDAQ: AYTU) Heats Up The Summer With Natesto and MiOXSYS Updates; Pipeline Has Billion Dollar Market Potential
Jul 11, 2019 (AB Digital via COMTEX) —
The summer of 2019 is shaping up to become a power packed season for Aytu BioScience, Inc. (AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. Last week, AYTU, announced that it has been added to the Russell Microcap® Index effective July 1, 2019, and before that announcement, AYTU spent the week in Vienna at the ESHRE conference where it presented compelling data from its MiOXSYS® device. The key presentations demonstrated the devices predictive power to measure oxidation-reduction potential (ORP), a diagnostic output of the MiOXSYS® System, in determining fertilization outcomes following artificial insemination procedures. The news from the ESHRE conference sent the shares higher by more than 6% to trade at a current YTD increase of roughly 120%.
Video Link: http://www.youtube.com/embed/SUQ1zh781p0
And, while MiOXSYS® may have stolen the show during the past several weeks with announcements that the device will be expanding into the Australian, United Kingdom, and Chinese markets, investors should not lose focus of a potential near-term catalyst from Natesto®, the only FDA-approved nasally-administered testosterone replacement therapy drug on the market. For its part, investors and analysts are paying close attention to the soon to be released study results from the company’s co-sponsored Natesto® Spermatogenesis Study. These final results, expected later this summer, may confirm the already published interim data that show the potential for Natesto® to emerge as the only FDA-approved TRT on the market able to provide the benefits of testosterone therapy while at the same time preserving male fertility.
Thus, not only has MiOXSYS® positioned itself as a best-in-class device to measure oxidative stress associated to male infertility,